CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
Fluzoparib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04228601
NCT04228601Phase 2Completed
CompareCT.gov

A Phase Ib/II Study to Assess the Tolerability, Safety and Efficacy of Fluzoparib in Combination With mFOLFIRINOX Followed by Fluzoparib Maintenance Monotherapy in Patients With Advanced Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Jan 14, 2020·Updated Aug 16, 2024

In Brief

A Phase 2 clinical trial evaluating Fluzoparib, Fluzoparib placebo, and 1 other intervention for Advanced Pancreatic Cancer. Completed, enrolled 39 participants across 2 sites.

Detailed Summary

The study is being conducted to: a) evaluate the tolerability and safety of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer, and establish the maximum tolerated dose and recommended phase II dose of the combination; and b) assess the efficacy of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Pancreatic Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 14, 2020
Enrollment StartJan 21, 2020
Primary CompletionAug 10, 2022
Study CompletionJan 15, 2023
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 6.5 years ago

Interventions

Fluzoparibdrug

PARP

Fluzoparib placebodrug

Placebo

mFOLFIRINOXdrug

mFOLFIRINOX